Customer Service: Call 1-888-271-5237 Monday-Friday, 9 AM - 5 PM CT
Forgot Username or Password?
Shares have been on a tear this year, but investors still have time to jump on board.
Since this ETF began trading, a buy-and-hold investor would have lost about 18%, while a trader following this system would have seen gains of more than 80%.
While most of the sector was in rally mode over the past year, this stock was left behind. But the technicals show it's in the midst of a bullish turnaround.
Business slumped as stimulus funds dried up, but a rebound is clearly at hand for this company with a "billion-dollar backlog."
After shedding nearly 20% of their value, shares staged a bullish reversal and are set to head higher.
Whether you're looking for income or capital gains, this diversified utility has huge potential.
Sentiment is far from bullish extremes, while shares continue breaking out of one consolidation period after another. Buy at this level.
With a potentially lucrative product pipeline and proprietary drug delivery system, this little biotech could soar on positive trial results or a buyout offer.
If you want excitement, go to the race track. If you want solid double-digit gains, the technicals point to this under-the-radar stock.
Years of advanced research are about to yield a major payoff for this technology pioneer and could boost shares nearly 50%.